Carbapenem Resistant Pathogens: Epidemiology, Treatment and Prevention
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: 15 September 2024 | Viewed by 1793
Special Issue Editor
Special Issue Information
Dear Colleagues,
Antimicrobial resistance is an urgent and contemporary danger to public health. Carbapenem resistance is a wide umbrella definition encompassing both nonfermenters (e.g., A. baumannii, P. aeruginosa) and fermenters (e.g., Enterobacterales) but comprises distinct resistance mechanisms and molecular epidemiology that varies regionally. Carbapenem-resistant pathogens tend to harbor numerous mechanisms of resistance, drug inactivation through carbapenemase enzyme production being the most recognized. However, the proliferation of diverse carbapenemase, non-carbapenemase, and non-enzymatic mechanisms demands a shift in how these organisms are identified and managed. Adding to the complexity of the current challenges with carbapenem resistance includes inconsistent definitions among regulatory bodies and lack of specific infection prevention measures and limitations in rapid diagnostics corresponding to the diverse mechanisms underlying carbapenem resistance. Thus, there is a need for global investigations into emerging mechanisms and epidemiology underlying these evasive organisms and into the effectiveness of treatments that can guide clinicians and public health agencies to efficiently diagnose, treat, and prevent the spread of these organisms. Topics welcome for submission to this Special Issue include, but are not limited to:
- Emerging mechanisms and features underlying non-carbapenemase-producing, carbapenem-resistant organisms;
- Comparative infection prevention measures targeting carbapenem-resistant organisms;
- Therapeutic approaches to non-carbapenemase-producing, carbapenem-resistant organisms;
- Novel diagnostic methods for carbapenem resistance with translational application in the clinic;
- Emerging resistance to non-carbapenem (e.g., polymyxin, fosfomycin) or carbapenem-beta lactamase agents (e.g., meropenem-vaborbactam);
- Epidemiological investigations in vulnerable or immunocompromised populations (e.g., bone marrow transplant);
- Impact of COVID-19 on regional variation in antimicrobial utilization and infection prevention measures with shifts in epidemiology of carbapenem-resistant organisms.
Dr. Grace C. Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- carbapenem resistance
- epidemiology
- Gram-negative
- carbapenemase
- non-carbapenemase
